TBPH Q3 2023 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+26.0% YoY

Gross Profit

$14M91.5% margin

Operating Income

-$9M-55.8% margin

Net Income

-$9M-57.0% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+14.1%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$3M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$414M

Total Liabilities

$167M

Stockholders' Equity

$246M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$12M	+26.0%
Gross Profit	$14M	$3M	+455.5%
Operating Income	-$9M	-$14M	+38.3%
Net Income	-$9M	$917M	-101.0%

Revenue Segments

YUPELRI Monotherapy

$20M100%

Collaboration revenue

$6,0000%